89 related articles for article (PubMed ID: 28927900)
1. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions.
Tangen IL; Veneris JT; Halle MK; Werner HM; Trovik J; Akslen LA; Salvesen HB; Conzen SD; Fleming GF; Krakstad C
Gynecol Oncol; 2017 Dec; 147(3):672-677. PubMed ID: 28927900
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor as potential therapeutic target in metastatic endometrial cancer.
Tangen IL; Onyango TB; Kopperud R; Berg A; Halle MK; Øyan AM; Werner HM; Trovik J; Kalland KH; Salvesen HB; Krakstad C
Oncotarget; 2016 Aug; 7(31):49289-49298. PubMed ID: 27384477
[TBL] [Abstract][Full Text] [Related]
3. Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.
Fonnes T; Berg HF; Bredholt T; Edqvist PD; Sortland K; Berg A; Salvesen HB; Akslen LA; Werner HMJ; Trovik J; Tangen IL; Krakstad C
Gynecol Oncol; 2018 Jan; 148(1):197-203. PubMed ID: 29096882
[TBL] [Abstract][Full Text] [Related]
4. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.
Halle MK; Tangen IL; Berg HF; Hoivik EA; Mauland KK; Kusonmano K; Berg A; Hurtado A; Kalland KH; Øyan AM; Stefansson I; Vintermyr OK; Werner HM; Haldorsen IS; Trovik J; Salvesen HB; Krakstad C
Br J Cancer; 2018 Feb; 118(3):378-387. PubMed ID: 29169184
[TBL] [Abstract][Full Text] [Related]
5. Switch in FOXA1 status associates with endometrial cancer progression.
Tangen IL; Krakstad C; Halle MK; Werner HM; Oyan AM; Kusonmano K; Petersen K; Kalland KH; Akslen LA; Trovik J; Hurtado A; Salvesen HB
PLoS One; 2014; 9(5):e98069. PubMed ID: 24849812
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Genomic Crosstalk between Glucocorticoid Receptor and Estrogen Receptor α In Endometrial Cancer.
Vahrenkamp JM; Yang CH; Rodriguez AC; Almomen A; Berrett KC; Trujillo AN; Guillen KP; Welm BE; Jarboe EA; Janat-Amsbury MM; Gertz J
Cell Rep; 2018 Mar; 22(11):2995-3005. PubMed ID: 29539426
[TBL] [Abstract][Full Text] [Related]
7. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
[TBL] [Abstract][Full Text] [Related]
8. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
9. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.
Allegra JC; Lippman ME; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC
Cancer Res; 1979 May; 39(5):1447-54. PubMed ID: 427788
[TBL] [Abstract][Full Text] [Related]
10. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.
Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D
Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443
[TBL] [Abstract][Full Text] [Related]
11. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.
Tangen IL; Werner HM; Berg A; Halle MK; Kusonmano K; Trovik J; Hoivik EA; Mills GB; Krakstad C; Salvesen HB
Eur J Cancer; 2014 Nov; 50(17):3003-10. PubMed ID: 25281525
[TBL] [Abstract][Full Text] [Related]
12. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.
Mauland KK; Wik E; Hoivik EA; Kusonmano K; Halle MK; Berg A; Haugland HK; Øyan AM; Kalland KH; Stefansson IM; Akslen LA; Krakstad C; Trovik J; Werner HM; Salvesen HB
Oncotarget; 2017 Feb; 8(6):9696-9707. PubMed ID: 28039471
[TBL] [Abstract][Full Text] [Related]
13. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
14. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
Köbel M; Atenafu EG; Rambau PF; Ferguson SE; Nelson GS; Ho TC; Panzarella T; McAlpine JN; Gilks CB; Clarke BA; Bernardini MQ
Gynecol Oncol; 2016 Jun; 141(3):559-563. PubMed ID: 27072807
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of BAF57 expression in patients with endometrial carcinoma.
Kagami S; Kurita T; Kawagoe T; Toki N; Matsuura Y; Hachisuga T; Matsuyama A; Hashimoto H; Izumi H; Kohno K
Histol Histopathol; 2012 May; 27(5):593-9. PubMed ID: 22419023
[TBL] [Abstract][Full Text] [Related]
16. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium.
Arnett-Mansfield RL; deFazio A; Wain GV; Jaworski RC; Byth K; Mote PA; Clarke CL
Cancer Res; 2001 Jun; 61(11):4576-82. PubMed ID: 11389093
[TBL] [Abstract][Full Text] [Related]
17. Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer.
Tomica D; Ramić S; Danolić D; Šušnjar L; Perić-Balja M; Puljiz M
J Obstet Gynaecol; 2018 Jan; 38(1):96-102. PubMed ID: 28764605
[TBL] [Abstract][Full Text] [Related]
18. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
19. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
[TBL] [Abstract][Full Text] [Related]
20. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
